Key Highlights
- Elevance fell as managed care stocks posted a second straight day of steep losses.
- The CMS proposal was released Monday and would broaden Medicare Advantage audits.
- Humana was the S&P 500's worst performer and UnitedHealth the Dow's biggest drag.
- Health care was the second-worst S&P 500 sector, behind only energy.
Insurers under pressure again
Elevance Health (NYSE:ELV) sank during Wednesday's session, part of a second straight day of steep losses for managed-care stocks. The selling followed a proposed rule from the Centers for Medicare & Medicaid Services, released Monday, that would broaden audits of payments to Medicare Advantage plans.
Elevance had plenty of company. Humana (NYSE:HUM) was the worst performer in the S&P 500, UnitedHealth Group (NYSE:UNH) was the biggest drag on the Dow Jones Industrial Average, and Centene (NYSE:CNC), CVS Health (NYSE:CVS), Cigna (NYSE:CI) and Molina Healthcare (NYSE:MOH) all fell sharply. Health care was the second-worst sector in the S&P 500 on the day, behind only energy.
The Dow lost 561.25 points to close at 50,198.17, with health care pushing it to its session low. The S&P 500 slipped 16.90 points to 7,323.63, its fifth straight loss and longest losing streak since June.
Inside the CRUSH proposal
The rule is called Comprehensive Regulations to Uncover Suspicious Healthcare, or CRUSH. It would allow CMS to take findings from risk adjustment data validation audits, known as RADV audits, on a sample of medical records and extrapolate them to an entire Medicare Advantage contract, starting with payment year 2018.
RADV audits check whether the diagnoses insurers report, which raise payments for sicker members, are backed by medical records. Extrapolation can greatly increase the amounts the government seeks to recover. CMS estimates the rule could save about $90 billion over 10 years.
CMS Administrator Dr. Mehmet Oz framed the proposal as a way to "crush fraud, waste, and abuse." The rule sets audit methods for the whole program and does not single out any insurer. It is not final, and CMS is accepting comments until January 19, 2027.
The proposal revives a 2023 RADV rule that a Texas federal judge vacated in September 2025 in a case brought by Humana.
Where Elevance fits
Elevance is one of the largest US health insurers. It operates Anthem Blue Cross and Blue Shield plans in many states and serves members through employer coverage, individual plans, Medicaid and Medicare, including Medicare Advantage. It also runs Carelon, its health services arm.
That breadth means Elevance is less concentrated in Medicare Advantage than Humana, and its decline, while steep, was smaller than its rival's. Still, Medicare Advantage is an important Business for the company, and any change to how payments are audited and recovered could affect its earnings.
The analyst view
One analyst said that "The substantially larger collection estimate reflects broader auditing," and that CMS "could choose to make adjustments in the final rule." Oppenheimer expects legal challenges and believes plans would price the cost into their bids.
That bid point matters. Medicare Advantage insurers submit annual bids that set benefits and premiums, so a higher expected audit cost could, over time, show up in plan design rather than solely in profits.
UnitedHealth's Outlook as a Guide for Elevance Investors
The comment period through January 19, 2027, is the next formal step, and CMS could modify the proposal before finalizing it. Investors will watch for any statements from Elevance on how it views the rule's potential financial effect.
UnitedHealth plans to issue its 2027 outlook before year-end, which could offer an industry read on how insurers are planning around the proposal. Broader market forces also loom, including the Federal Reserve's December 8 to 9 meeting, after minutes released Wednesday showed almost all participants judged further rate increases would likely be appropriate.

_11_19_2026_12_45_47_957380.jpg)
_11_19_2026_12_45_58_729375.jpg)



Please wait processing your request...